Skip to main contentFREE SHIPPING THRESHOLD$250 REMAINING
MK-IV SPEC
LAT: 34.0522° NLONG: 118.2437° W
RESEARCH ONLYOA-1053-MT1
MT-1
Synthetic Analog Of Alpha-Msh
UNIT COST$34.00
STATUSIN STOCK
QTY
1
MISSION CRITICAL: For in vitro laboratory research only. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+.
SPECIFICATIONS
CAS No.75921-69-6
Mol. Weight1646.87 g/mol
Purity≥99.0% (HPLC)
FormLyophilized Powder
Storage−20°C · Lyophilized
Mol. FormulaC78H111N21O19
COMPOUND INTEL
REF #OA-1053-MT1MECHANISM_DUMP
MOLECULAR PROFILE
Melanotan-1 (MT-1) is a synthetic analog of alpha-MSH and full-length 13-amino acid linear peptide. With the molecular formula C₇₈H₁₁₁N₂₁O₁₉ and a molecular weight of 1646.8 g/mol (CAS: 75921-69-6), it structurally mimics endogenous peptides while extending its sequence.
AMINO ACID SEQUENCE
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2Synthetic Analog Of Alpha-MshMelanocortin 1 Receptor (MC1R)Melanin generation pathway
MECHANISM OF ACTION
Melanocortin 1 Receptor (MC1R)Receptor interaction
Published research demonstrates Melanotan-1 (MT-1) modulates targeted signaling cascades within cell tissue models (PMID: 33865932).
Melanin generation pathwaySignaling cascade
In cellular environments, Melanotan-1 (MT-1) exhibits selective binding and corresponding pathway activation (PMID: 32167144).
TECHNICAL DATA
- CAS No.
- 75921-69-6
- Mol. Formula
- C78H111N21O19
- Mol. Weight
- 1646.87 g/mol
- Purity
- ≥99.0% (HPLC)
- Form
- Lyophilized Powder
- Storage
- −20°C · Lyophilized
PMID REFERENCE LIBRARY
PMID: 33865932
Lonati et al. (2021) investigated Melanotan-1 (MT-1)'s binding affinity and receptor interactions in vitro (PMID: 33865932).
Lonati C, et al. (2021). NDP-MSH treatment recovers marginal lungs during ex vivo lung perfusion (EVLP). Peptides.PMID: 32167144Qiao et al. (2020) investigated Melanotan-1 (MT-1)'s binding affinity and receptor interactions in vitro (PMID: 32167144).
Qiao Y, et al. (2020). Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling. Clin Sci (Lond).
